Curocell

Curocell Current Assets

The Current Assets of Curocell (372320.KQ) as of Oct 27, 2026 is 1.68 B KRW. In the previous year, Current Assets was 11.95 B KRW — a change of -85.93% (lower).

Current Assets

1.68 BKRW

YoY

-85.93%

Last updated:

Current Assets of Curocell is 2025 1.68 B KRW. Current Assets of Curocell was 2024 11.95 B KRW. It decreases by -85.93% lower compared to the previous year.

The Curocell Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2021
615.88 M KRW
Jan 1, 2022
41.31 B KRW
Jan 1, 2023
42.66 B KRW
Jan 1, 2024
11.95 B KRW
Jan 1, 2025
1.68 B KRW
The Curocell Current Assets history
YEARCurrent AssetsYoY
1.68 BKRW-85.93%
11.95 BKRW-71.99%
42.66 BKRW+3.28%
41.31 BKRW+6,607.33%
615.88 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

Current Assets of Curocell is 1.68 B KRW in 2025.

Current Assets of Curocell changed from 11.95 B KRW to 1.68 B KRW, representing a -85.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Curocell since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Curocell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Curocell

All Key Metrics — Curocell